Congress gave money for global HIV work. The Trump administration isn’t spending it – NPR

The United States Congress has consistently appropriated substantial funds for critical global HIV/AIDS programs, yet reports indicate that the Trump administration significantly delayed or withheld the disbursement of these allocated monies. This inaction has raised considerable concern among lawmakers, public health experts, and international partners, threatening the progress achieved in combating the global HIV epidemic and potentially undermining U.S. leadership in global health. The delays span multiple fiscal years, affecting various initiatives designed to prevent new infections, provide life-saving treatment, and support health infrastructure in vulnerable nations worldwide.

Background

The United States has long been a pivotal force in the global fight against HIV/AIDS, a commitment solidified by the establishment of the President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003. This bipartisan initiative, launched under President George W. Bush, marked an unprecedented scale of U.S. engagement in addressing a single disease pandemic on a global scale. From its inception, PEPFAR garnered broad support across the political spectrum, reflecting a shared understanding of the humanitarian imperative and strategic importance of combating HIV/AIDS worldwide.

The Genesis of U.S. Global HIV/AIDS Efforts

Before PEPFAR, U.S. efforts against global HIV/AIDS were largely fragmented, comprising various bilateral programs and contributions to multilateral organizations. The early 2000s saw a growing recognition of the devastating impact of the epidemic, particularly in sub-Saharan Africa, where millions were dying annually, and entire societies faced collapse. This crisis spurred calls for a more coordinated and robust international response.

PEPFAR was designed as a comprehensive program, providing funding for prevention, treatment, and care initiatives in the hardest-hit countries. Its primary goals included dramatically expanding access to antiretroviral treatment (ART), preventing mother-to-child transmission (PMTCT), supporting orphans and vulnerable children, and strengthening health systems. The program quickly became a cornerstone of U.S. foreign policy and a beacon of hope for millions.

PEPFAR’s Impact and Funding Mechanisms

Over its two decades of operation, PEPFAR has achieved remarkable successes. It is credited with saving over 25 million lives, preventing millions of new HIV infections, and significantly altering the trajectory of the global epidemic. Its integrated approach has strengthened health systems, built laboratory capacity, trained healthcare workers, and improved data collection in dozens of countries. The program’s focus on evidence-based interventions and country ownership has been critical to its effectiveness.

Funding for PEPFAR primarily flows through two main channels: direct bilateral aid to partner countries, managed by the U.S. Department of State's Office of the Global AIDS Coordinator (OGAC) and implemented by agencies like USAID and the Centers for Disease Control and Prevention (CDC); and contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a multilateral partnership designed to attract and disburse resources to prevent and treat HIV/AIDS, TB, and malaria. U.S. contributions to the Global Fund are statutorily capped at one-third of the total contributions from all donors to encourage burden-sharing.

Congressional Authorization and Appropriations Process

PEPFAR’s activities and funding levels are determined annually through the congressional appropriations process. Congress, specifically the House and Senate Appropriations Committees, reviews the President’s budget request and then crafts appropriations bills, often specifying amounts for global health programs, including dedicated lines for PEPFAR bilateral programs and the Global Fund. These appropriations represent the maximum amount of money an agency can obligate or spend in a given fiscal year.

The legislative process involves extensive hearings, markups, and negotiations, culminating in the passage of omnibus appropriations bills or individual spending measures. Throughout this process, PEPFAR has historically enjoyed strong bipartisan support, with members of Congress often advocating for consistent or increased funding levels, even when presidential administrations proposed cuts. This reflects a deep-seated belief in the program's effectiveness and its strategic value to U.S. foreign policy.

Funding Trajectory and Administrative Transitions

From its initial allocation of $15 billion over five years, PEPFAR’s funding grew steadily, peaking at over $6.8 billion in Fiscal Year 2008. While subsequent years saw some fluctuations, annual appropriations generally remained robust, typically ranging between $4.5 billion and $5.5 billion. This sustained investment allowed PEPFAR to expand its reach and deepen its impact, particularly in scaling up antiretroviral treatment.

The transition to the Trump administration in 2017 introduced a new dynamic. The administration's "America First" foreign policy doctrine often translated into proposals for significant reductions in foreign assistance, including global health programs. For instance, the administration's budget requests for Fiscal Years 2018, 2019, and 2020 consistently proposed cuts to PEPFAR and other global health initiatives, sometimes by more than $1 billion annually. However, Congress, demonstrating its continued bipartisan commitment to these programs, largely rejected these proposed cuts. In many instances, Congress appropriated funds at levels similar to or slightly above previous years, explicitly overriding the administration's requests. This set the stage for potential tensions between congressional intent and executive branch implementation regarding the disbursement of these funds.

Key Developments

The divergence between congressional appropriations and the Trump administration’s spending priorities became particularly evident through reports of significant delays in disbursing funds allocated for global HIV/AIDS work. This development sparked concern across various sectors, leading to increased scrutiny and calls for accountability.

Emergence of the Unspent Funds Issue

Reports began to surface, initially through investigative journalism and later corroborated by congressional inquiries and advocacy groups, indicating a substantial slowdown in the obligation and expenditure of congressionally appropriated funds for global HIV/AIDS programs. These delays were not merely administrative lags but appeared to be a deliberate holding of funds by the executive branch. The issue gained prominence around Fiscal Year 2018 and continued into subsequent fiscal years, with hundreds of millions of dollars reportedly being held back.

The mechanism of delay varied, but often involved funds being held at the Office of Management and Budget (OMB), within the State Department's Office of the Global AIDS Coordinator (OGAC), or at USAID, preventing them from reaching implementing partners on the ground. This meant that while Congress had legally authorized and appropriated the money, it was not being committed to programs or disbursed to organizations responsible for delivering services.

Specific Fiscal Years and Amounts

The unspent funds issue affected multiple fiscal years. For instance, reports indicated that significant amounts from the FY22018 appropriation for global HIV/AIDS programs remained unobligated well into FY2019. Similarly, appropriations for FY2019 faced similar delays. While exact figures fluctuated as some funds were eventually released, estimates often placed the delayed amounts in the range of $200 million to $500 million across various programs and fiscal years. These figures represented a substantial portion of the annual budget for global HIV/AIDS work.

Affected Programs and Initiatives

The delayed funds impacted a wide array of critical global HIV/AIDS initiatives. These included:
* Antiretroviral Drug Procurement: Delays in funding could disrupt the supply chain for life-saving antiretroviral drugs (ARVs), essential for treating people living with HIV and preventing new infections.
* Prevention Programs: Initiatives focused on HIV prevention, such as the DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) program for adolescent girls and young women, comprehensive condom distribution, and pre-exposure prophylaxis (PrEP) programs, faced uncertainty.
* Testing and Counseling Services: Funding for HIV testing, crucial for identifying new cases and linking individuals to care, was also affected.
* Health Systems Strengthening: Efforts to build robust health infrastructure, train healthcare workers, and improve laboratory capacity, which are foundational to sustainable HIV responses, experienced setbacks.
* Global Fund Contributions: While the U.S. is a major donor to the Global Fund, delays in pledging or disbursing U.S. contributions could undermine the Fund’s ability to plan and implement its global programs.

These delays had a ripple effect, impacting programs in numerous countries, particularly in sub-Saharan Africa, which bears the brunt of the global HIV epidemic.

Administration’s Stance and Explanations

The Trump administration offered various explanations for the delayed spending, often citing a need for “programmatic review,” “efficiency improvements,” and “ensuring proper use of taxpayer money.” Officials from OMB and the State Department sometimes suggested that the delays were part of a broader effort to optimize foreign aid spending and eliminate waste, fraud, and abuse. Some arguments implied that the funds were not truly being “held” but rather were undergoing a meticulous review process to ensure alignment with administration priorities or to identify more effective ways of spending.

However, critics argued that these explanations were vague and lacked specific justification for holding funds that Congress had explicitly appropriated for established, high-impact programs. The administration's rhetoric often focused on reducing foreign aid outlays, creating an impression that the delays were a tactic to achieve de facto budget cuts despite congressional mandates.

Congressional Response and Oversight

The reported delays triggered significant alarm and a strong bipartisan response from Congress. Members of both the House and Senate, particularly those on the Appropriations, Foreign Relations, and Global Health Subcommittees, expressed deep concern. They viewed the administration’s actions as a potential circumvention of congressional authority and a threat to U.S. foreign policy objectives.

Congressional leaders sent multiple letters to the administration, demanding explanations for the delays and urging the immediate release of funds. Hearings were convened where administration officials were pressed to justify the withholding of appropriations. Lawmakers emphasized that Congress, not the executive branch, holds the "power of the purse" and that funds appropriated for specific purposes must be spent as intended. Some members threatened legislative action, such as writing more restrictive language into future appropriations bills or pursuing legal remedies, if the funds were not released.

Legal Framework: The Impoundment Control Act of 1974

A critical aspect of this dispute revolved around the Impoundment Control Act of 1974. This Act was passed in response to President Richard Nixon’s widespread impoundment of congressionally appropriated funds, an action that Congress viewed as an overreach of executive power. The Act prohibits the President from unilaterally withholding or delaying the expenditure of appropriated funds. It stipulates that if the President wishes to “rescind” (cancel) or “defer” (delay) funds, he must notify Congress. Congress then has a specified period to approve or reject the proposed rescission or deferral. If Congress does not approve, the funds must be released.

Critics of the Trump administration's actions argued that the prolonged and unexplained delays in obligating global HIV/AIDS funds amounted to an illegal impoundment, bypassing the procedures outlined in the 1974 Act. They contended that the administration was effectively achieving a rescission or deferral without congressional approval, thereby undermining the separation of powers and congressional authority over federal spending. The Government Accountability Office (GAO), a non-partisan investigative arm of Congress, has historically played a role in interpreting and enforcing the Impoundment Control Act, and its potential involvement was often cited in discussions surrounding these delays.

Impact

The prolonged delays in disbursing congressionally appropriated funds for global HIV/AIDS work generated a cascade of negative consequences, affecting program implementation, the lives of beneficiaries, the credibility of implementing partners, and the broader standing of the United States in global health leadership.

On Program Implementation and Beneficiaries

The most immediate and severe impact of the funding delays was felt on the ground, where critical HIV/AIDS programs faced disruption and uncertainty.

Disruption of Services

Implementing partners, including local and international non-governmental organizations (NGOs) and national health ministries, rely on predictable funding streams to plan and execute their programs. Delays in fund disbursement led to:
* Supply Chain Disruptions: Procurement of essential medicines, such as antiretroviral drugs (ARVs), HIV testing kits, laboratory reagents, and condoms, faced delays. For individuals living with HIV, interruptions in ARV treatment can lead to drug resistance, treatment failure, and increased viral load, making them more likely to transmit the virus and experience disease progression.
* Stalled Program Expansion: Many programs aim to scale up successful interventions, such as expanding access to PrEP for high-risk populations or increasing the number of people on ART. Funding delays meant these expansions were often put on hold or significantly slowed, limiting the reach of life-saving services.
* Reduced Prevention Efforts: Prevention programs, including those targeting key populations (men who have sex with men, sex workers, injecting drug users) and adolescent girls and young women (like the DREAMS initiative), faced funding shortfalls, reducing their capacity to conduct outreach, provide education, and distribute prevention commodities.
* Weakened Health Systems: Efforts to strengthen local health systems, including training healthcare workers, improving data management, and enhancing laboratory infrastructure, were hampered. These foundational activities are crucial for sustainable HIV responses beyond direct service delivery.

Increased Risk of HIV Transmission and Mortality
The direct consequence of service disruptions is an elevated risk of HIV transmission and, in some cases, increased mortality. When individuals cannot access consistent treatment or prevention services, the gains made in epidemic control are jeopardized. For example, if a pregnant woman living with HIV cannot access PMTCT services due to funding delays, her child is at a higher risk of acquiring HIV. Similarly, treatment interruptions among people living with HIV can lead to a rebound in viral load, increasing the risk of onward transmission.

Impact on Vulnerable Populations
Vulnerable populations, who often face structural barriers to accessing healthcare, were disproportionately affected. Adolescent girls and young women, who bear a significant burden of new HIV infections in many regions, rely on comprehensive prevention programs. Key populations, often marginalized and stigmatized, depend on targeted services that may be the first to be cut during funding crises. The delays exacerbated existing inequalities and threatened to reverse progress in reaching these critical groups.

On Implementing Partners and NGOs

The operational challenges faced by implementing partners were significant.

Uncertainty in Funding Streams

NGOs and local organizations operate on tight budgets and require clear financial commitments to plan their activities, hire staff, and commit to procurements. The uncertainty created by delayed U.S. funding made long-term planning virtually impossible, forcing organizations to operate in a perpetual state of limbo. This uncertainty can lead to a “stop-start” cycle, which is inefficient and undermines program quality.

Staffing Issues
Many programs rely on local staff—doctors, nurses, counselors, community health workers—who are essential for delivering services. Funding delays often resulted in hiring freezes, non-renewal of contracts, or even layoffs, leading to a loss of experienced personnel and institutional knowledge. Rebuilding these teams once funds are eventually released is a slow and costly process.

Erosion of Trust
The U.S. government, through PEPFAR, has built strong relationships with partner governments and implementing organizations over two decades. The funding delays eroded this trust, causing partners to question the reliability and commitment of the U.S. as a donor. This erosion of trust can have long-lasting implications for future collaborations and the effectiveness of U.S. foreign assistance.

On U.S. Global Health Leadership and Diplomacy

The delays in funding also had broader implications for U.S. standing on the international stage.

Damage to U.S. Reputation

The U.S. has been widely recognized as the global leader in the fight against HIV/AIDS, a position earned through sustained financial commitment and technical expertise. The withholding of funds damaged this reputation, leading other donor nations and international bodies to question the consistency and predictability of U.S. support. This can undermine multilateral efforts and the overall global health agenda.

Undermining Bipartisan Investment
PEPFAR's success is a testament to consistent bipartisan support. The administration's actions risked undermining this legacy and jeopardizing years of diplomatic effort and financial investment. It sent a message that U.S. commitments could be subject to political whims, regardless of congressional intent.

Soft Power Implications
Global health initiatives, particularly PEPFAR, represent a significant component of U.S. "soft power"—the ability to influence through attraction rather than coercion. By saving millions of lives and strengthening health systems, PEPFAR has fostered goodwill and strengthened diplomatic ties with numerous countries. The funding delays threatened to diminish this soft power, potentially impacting U.S. influence on other foreign policy issues.

On the Global Fight Against HIV/AIDS

The global community has set ambitious targets, such as the UNAIDS 95-95-95 goals (95% of people living with HIV know their status, 95% of those diagnosed are on treatment, and 95% of those on treatment achieve viral suppression). Consistent and predictable funding is paramount to achieving these targets.

Threat to Epidemic Control

The delays threatened to stall or reverse progress towards epidemic control in many countries. HIV is a dynamic epidemic; any slowdown in prevention or treatment efforts can quickly lead to a resurgence in new infections. The concept of “momentum” is crucial in public health, and disrupting it can have exponential negative effects.

Challenges to Sustainable Development Goals
The fight against HIV/AIDS is intrinsically linked to the United Nations Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being). U.S. funding delays complicated efforts to meet these broader global development objectives, impacting not only health outcomes but also social and economic stability in affected regions.

In summary, the decision to delay or withhold congressionally appropriated funds for global HIV/AIDS programs had far-reaching and detrimental effects, undermining public health, damaging diplomatic relations, and threatening to reverse decades of hard-won progress against one of the world's most persistent pandemics.

What Next

The issue of unspent global HIV funds highlighted a significant tension between congressional intent and executive branch discretion, prompting ongoing debate and various actions aimed at resolving the situation and preventing similar occurrences in the future.

Ongoing Congressional Pressure

Members of Congress continued to exert pressure on the administration to release the delayed funds. This pressure manifested in several ways:

Oversight Hearings

Congressional committees, particularly the House and Senate Appropriations Committees and Foreign Affairs/Relations Committees, continued to hold oversight hearings. During these sessions, administration officials, including those from the Office of Management and Budget (OMB), the State Department, and USAID, were called upon to explain the rationale behind the delays and to provide timelines for fund disbursement. These hearings served as public forums to highlight the issue and demand accountability.

Legislative Mandates and Report Language
In subsequent appropriations bills, Congress considered and sometimes included more explicit legislative language to mandate spending or set deadlines for the obligation and expenditure of funds. This could involve "earmarking" funds more precisely or adding clauses that restrict the executive branch's ability to withhold money. Additionally, committee "report language," which accompanies appropriations bills, often provides detailed instructions and expressions of congressional intent regarding how funds should be used, even if not legally binding in the same way as statutory text.

Government Accountability Office (GAO) Investigations
The Government Accountability Office (GAO), an independent, non-partisan agency that works for Congress, played a crucial role. Congress could formally request the GAO to investigate whether the administration's actions constituted an illegal impoundment under the Impoundment Control Act of 1974. A formal GAO ruling finding an impoundment would significantly strengthen Congress's hand in compelling the administration to release the funds.

Administration’s Potential Actions

The administration’s response to congressional pressure and public scrutiny could take several forms:

Release of Funds Under Pressure

In many instances, following sustained congressional and public pressure, the administration would eventually release some or all of the delayed funds. However, these releases often came late in the fiscal year, leaving implementing partners with limited time to obligate and expend the money effectively. The timing of such releases often suggested a reactive rather than proactive approach.

Continued Justification of Delays
The administration might continue to justify delays by reiterating arguments about programmatic review, efficiency, or the need to align spending with broader foreign policy objectives. This could involve issuing formal statements or providing detailed (though often disputed) explanations to congressional committees.

Rescission Proposals
The administration could formally propose rescinding (canceling) unspent funds. However, under the Impoundment Control Act, Congress must approve any proposed rescission. Given the strong bipartisan support for global HIV/AIDS programs, it was highly unlikely that Congress would approve such rescissions, effectively blocking the administration from permanently withholding the money.

Fiscal Year Cycles and Carryover Funds

The federal budgeting process operates on a fiscal year (FY) basis, running from October 1 to September 30.

Expiration of Funds

Most appropriated funds are “annual” funds, meaning they are available for obligation only during the fiscal year for which they were appropriated. If funds are not obligated by the end of that fiscal year, they typically expire and are no longer available for use, reverting to the Treasury. This creates a strong incentive for agencies to obligate funds promptly.

No-Year Funds and Carryover

However, some appropriations, particularly for certain foreign assistance programs, are designated as “no-year” funds, meaning they remain available for obligation until expended. Even for annual funds, some carryover mechanisms exist, allowing unobligated balances to be carried over into the next fiscal year under specific conditions. While carryover funds can provide flexibility, excessive carryover can signal inefficiencies or, in this case, deliberate delays, and can complicate future budget planning. The existence of significant carryover balances for global HIV/AIDS programs fueled concerns about the administration’s intent.

Role of Advocacy Groups and International Bodies

Advocacy groups, NGOs, and international organizations played a critical role in drawing attention to the issue and pressuring for action.

Continued Advocacy

Organizations like the Global Health Council, UNAIDS, and various HIV/AIDS advocacy groups consistently highlighted the human cost of funding delays. They published reports, issued press releases, engaged with policymakers, and mobilized public support to urge the administration to release the funds and ensure predictable support for global HIV programs.

Statements from International Bodies

International organizations such as UNAIDS and the World Health Organization (WHO), as well as the Global Fund to Fight AIDS, Tuberculosis and Malaria, often issued statements underscoring the importance of consistent U.S. funding and warning against the negative consequences of any disruptions. These statements reinforced the global consensus on the necessity of these programs.

Long-term Implications for Executive-Legislative Relations

The dispute over global HIV funds underscored a fundamental tension in the U.S. system of government: the balance of power between the executive branch’s role in implementing policy and Congress’s constitutional “power of the purse.”

Checks and Balances

This episode served as a significant test of the system of checks and balances. Congress’s ability to appropriate funds is a core constitutional power, and the executive branch’s obligation to spend those funds as intended is crucial for maintaining that balance. Challenges to this balance can have far-reaching implications for how future administrations interact with Congress on budgetary matters across various sectors.

Precedents for Future Administrations

How this specific issue was ultimately resolved could set precedents for future executive actions regarding appropriated